EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.

Abstract	High grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR expression is significantly correlated with family history and worse OS. HLA-G is associated with worse OS. To confirm the results of EGFR and HLA-G, a second separated cohort of 248 patients is used. Positive EGFR expression again shows worse OS, while HLA-G expression has worse prognostic trend. CD70 has a worse OS trend. C-MET and NY-ESO1 do not have any clinical correlations. EGFR can potentially serve as target in future clinical immune therapy trials.
Authors	Duc Vo, Yan Liu, Anil K Sood, Katy Rezvani, Amir A Jazaeri, Jinsong Liu
Journal	Cancer biomarkers : section A of Disease markers (Cancer Biomark) Vol. 39 Issue 4 Pg. 289-298 ( 2024) ISSN: 1875-8592 [Electronic] Netherlands
PMID	38250760 (Publication Type: Journal Article)
Chemical References	Biomarkers, Tumor Membrane Proteins Proto-Oncogene Proteins c-met ErbB Receptors CTAG1B protein, human EGFR protein, human Antigens, Neoplasm HLA-G Antigens MET protein, human
Topics	Humans Female Biomarkers, Tumor (metabolism) Membrane Proteins (metabolism) Proto-Oncogene Proteins c-met (metabolism) ErbB Receptors (metabolism) Carcinoma, Ovarian Epithelial (pathology, metabolism, mortality) Middle Aged Ovarian Neoplasms (metabolism, pathology, mortality) Prognosis Antigens, Neoplasm (metabolism) HLA-G Antigens (metabolism) Aged Adult Neoplasm Grading Immunohistochemistry Aged, 80 and over

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!